Apogee Therapeutics secures $1.3B Blackstone financing for Phase 3 drug launch
Apogee Therapeutics (NASDAQ:APGE) has entered into a strategic financing collaboration with Blackstone Life Sciences, securing up to $1.3 billion in flexible, non-dilutive capital.


_1407578_640x360_2501508675507-640x360.webp&w=3840&q=75)

_1407569_640x360_2501505603743-640x360.webp&w=3840&q=75)



_1407556_640x360_2501509699566-640x360.webp&w=3840&q=75)


_1407524_640x360_2501505603568-640x360.webp&w=3840&q=75)